Edwards Q1 sales $1.46B (+9% YoY), adj EPS $0.62; raises FY guidance, CEO to retire

Edwards Lifesciences Corp

2023-Q1 EPS reported $0.56 revenue$1,459,600,000

Q1 GAAP EPS $0.56; adjusted EPS $0.62 vs prior guidance implied range.
TAVR sales $948M (+8% YoY, +11% cc); TMTT $42M; Surgical $248M; Critical Care $222M.
Full-year sales guidance raised to high end of $5.6-6.0B; adj EPS guidance raised to $2.48-2.60.
Repurchased ~$250M stock in Q1; free cash flow $253M.
CEO Michael Mussallem retiring next month; Bernard Zovighian to succeed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Edwards Lifesciences Corp reported the quarter ended March 31, 2023 results: revenue $1.46 billion, EPS $0.56. Guidance raised.

Period: the quarter ended March 31, 2023
Revenue: $1.46 billion
EPS: $0.56
Guidance: raised
Result: reported results

Exact text from the filing

April 26, 2023 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2023. Highlights and Outlook • Q1 sales grew 9 percent to $1.46 billion; constant currency 1 sales grew 13 percent • Q1 TAVR sales grew 8 percent; constant currency sales grew 11 percent • Q1 EPS of $0.56; adjusted 1 EPS of $0.62 • Repurchased

View on SEC.gov

Browse all earnings releases →

Edwards Lifesciences Corp filing history →

Source: SEC EDGAR

accession 0001099800-23-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.